Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 14 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Sales of cardiovascular consumables were strong in the minimally invasive medical device sales business of 株式会社フォーム, while sales of large medical devices and high-value repair projects also contributed to results exceeding the assumptions made at the beginning of the fiscal year. In addition, the purchase price allocation related to the acquisition of the Faskia Group has been completed, and the amortization expenses for goodwill and customer-related assets have been finalized.
| Item | Details |
|---|---|
| Net Sales | ¥42,000 million → ¥44,500 million（+6.0%） |
| Operating profit | ¥460 million → ¥680 million（+47.8%） |
| Ordinary income | ¥380 million → ¥610 million（+60.5%） |
| Profit attributable to owners of the parent | ¥8 million → ¥230 million（+2,775.0%） |
| Net income per share | 1.35 yen and sen → 38.84 yen and sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 November 2025 |
| Previous-period results | Net sales: ¥21,489 million; operating profit: ¥288 million; ordinary profit: ¥308 million; net income attributable to owners of the parent: ¥152 million; earnings per share: ¥25.86 |
| Reason for the revision | Sales of cardiovascular consumables were strong in the minimally invasive medical device sales business of 株式会社フォーム, while sales of large medical devices and high-value repair projects also contributed to results exceeding the assumptions made at the beginning of the fiscal year. In addition, the purchase price allocation related to the acquisition of the Faskia Group has been completed, and the amortization expenses for goodwill and customer-related assets have been finalized. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the minimally invasive medical device sales business operated by 株式会社フォーム, a Faskia Group company, sales of cardiovascular consumables were strong, while sales of large medical devices and high-value repair projects also contributed to results exceeding the assumptions made at the beginning of the fiscal year. In addition, the purchase price allocation related to the acquisition of the Faskia Group has been completed, and the amortization expenses for goodwill and customer-related assets have been finalized.